Hexarelin is one of the most potent synthetic GHRP compounds, associated with robust GH release and additional cardioprotective receptor activity. Mod GRF 1-29 (CJC-1295 without DAC) is a truncated GHRH analog that provides pulsatile GH stimulation without pituitary desensitization. This pairing is commonly researched for maximizing GH secretion through complementary GHRH and GHRP receptor activation.
Mechanism
Potent synthetic GHRP that activates GHS-R1a and CD36 receptors, producing robust GH pulses alongside documented cardioprotective receptor activity.
Truncated GHRH analog (CJC-1295 without DAC) that drives pulsatile pituitary GH secretion with a short active window that preserves the natural GH rhythm.
Dual-pathway activation
Hexarelin × Mod GRF 1-29
Hexarelin is associated with transient increases in cortisol and prolactin at higher research doses; periodic cycling is commonly discussed in community research literature. Mod GRF 1-29's short half-life supports physiological GH pulsatility. No formal human combination trial exists.
Per-component source only — no combination study exists
Hexarelin, a growth hormone-releasing peptide, directly stimulates pituitary somatotrophs in vitro
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
AOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.
⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Newsletter
The Peptide Research Digest
New providers, emerging stacks, and research developments — weekly.